TITLE

Vital Signs: Prevalence, Treatment, and Control of High Levels of Low-Density Lipoprotein Cholesterol -- United States, 1999-2002 and 2005-2008

AUTHOR(S)
Kuklina, E. V.; Shaw, K. M.; Hong, Y.
PUB. DATE
February 2011
SOURCE
MMWR: Morbidity & Mortality Weekly Report;2/4/2011, Vol. 60 Issue 4, p109
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Background: High levels of low-density lipoprotein cholesterol (LDL-C), a major risk factor for coronary heart disease (CHD), can be treated effectively. Methods: CDC analyzed data from 1999-2002 and 2005-2008 to examine the prevalence, treatment, and control of high LDL-C among U.S. adults aged =20 years. Values were determined from blood specimens obtained from persons participating in the National Health and Nutrition Examination Survey (NHANES), a nationally representative cross-sectional, stratified, multistage probability sample survey of the U.S. civilian, noninstitutionalized population. The National Cholesterol Education Program Adult Treatment Panel-III guidelines set LDL-C goal levels of <100 mg/dL, <130 mg/dL, and <160 mg/dL for persons with high, intermediate, and low risk for developing CHD during the next 10 years, respectively. A person with high LDL-C was defined as either a person whose LDL-C levels were above the LDL-C goal levels or a person who reported currently taking cholesterol-lowering medication. Control of high LDL-C was defined as having a treated LDL-C value below the goal levels. Results: Based on data from the 2005-2008 NHANES, an estimated 71 million (33.5%) U.S. adults aged =20 years had high LDL-C, but only 34 million (48.1%) were treated and 23 million (33.2%) had their LDL-C controlled. Among persons with uncontrolled LDL-C, 82.8% reported having some form of health insurance. The proportion of adults with high LDL-C who were treated increased from 28.4% to 48.1% between the 1999-2002 and 2005-2008 study periods. Among adults with high LDL-C, the prevalence of LDL-C control increased from 14.6% to 33.2% between the periods. The prevalence of LDL-C control was lowest among persons who reported receiving medical care less than twice in the previous year (11.7%), being uninsured (13.5%), being Mexican American (20.3%), or having income below the poverty level (21.9%). Conclusions: The prevalence of control of high LDL-C in the United States, although improving, remains low, especially among low-income adults and those with limited access to health care. Strengthening the use of preventive services through improvement in health-care access and quality of care is expected to help achieve better control of high LDL-C in the United States. Implications for Public Health Practice: To improve LDL-C control levels, a comprehensive approach that involves improved clinical care, as well as improved health-care access, sustainability, and affordability, is needed. A standardized system of patient care incorporating electronic health records, registries, and automated reminders for practitioners, focusing on achieving regular patient follow-up, has the potential to improve control of high LDL-C. Lower out-of-pocket costs and simplification of the drug regimen, as well as involvement of nurses, dietitians, health educators, pharmacists and other allied health-care professionals in direct patient care also could be used to improve patient adherence to prescribed regimens.
ACCESSION #
58692508

 

Related Articles

  • Hypoglycaemic and Hypolipidaemic Effects of Feed Formulated with Ceiba Pentandra Leaves in Alloxan Induced Diabetic Rats. Aloke, C.; Nachukwu, N.; Idenyi, J. N.; Ugwuja, E. I.; Nwachi, E. U.; Edeogu, C. O.; Ogah, O. // Australian Journal of Basic & Applied Sciences;2010, Vol. 4 Issue 9, p4473 

    In this study, the hypoglycaemic and hypolipidaemic effects of feed prepared with Ceiba pentandra leaves was investigated in alloxan induced diabetic rats. Twenty five (25) Wister albino male rats weighing 105-162g assigned into 5 groups (I-V) of 5 rats per group were investigated. Diabetes was...

  • LIPID MANAGEMENT.  // Monthly Prescribing Reference;Jan2014, Vol. 30 Issue 1, p20 

    The article focuses on low-density lipoprotein-cholesterol (LDL-C) as the main goal of lipid management. Topics include Therapeutic Lifestyle Changes (TLC) as the first-line therapy and reserve drug therapy for higher risk patients, doing lipoprotein analysis for in case of coronary heart...

  • Implementing the new ATP III cholesterol guidellines.  // Patient Care;Nov2002, Vol. 36 Issue 13, p19 

    Presents guidelines for clinical cholesterol management recommended by the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, also known as Adult Treatment Panel (ATP) III, released in May 2001. ...

  • "Best Evidence Yet" for Heart-Health Benefits of Nuts.  // Tufts University Health & Nutrition Letter;Aug2010, Vol. 28 Issue 6, p1 

    The article reports on the heart-health benefits of nuts which decrease low density lipoproteins (LDL) cholesterol levels in the U.S. Joan Sabaté of Loma Linda University says that eating nuts reduces coronary heart disease risk and improves the blood fats levels. Moreover, the researchers...

  • LIPID MANAGEMENT.  // Monthly Prescribing Reference;Feb2014, Vol. 30 Issue 2, p20 

    The article focuses on low-density lipoprotein-cholesterol (LDL-C) as the main goal of lipid management. Topics include Therapeutic Lifestyle Changes (TLC) as the first-line therapy and reserve drug therapy for higher risk patients, doing lipoprotein analysis for in case of coronary heart...

  • LIPID MANAGEMENT.  // Monthly Prescribing Reference;Oct2013, Vol. 29 Issue 10, p20 

    The article offers information on lipid management by lowering the content of lipid-density lipoproteins-cholesterol (LDL-C) in body. It mentions that Therapeutic Lifestyle changes (TLC) is the first-line reserve drug therapy for coronary heart disease (CHD) disorders. several tables are...

  • Non-HDL vs. LDL: Which Carries the Greater Risk? Orringer, Carl E. // Cardiology Today;Feb2012 Practical Lipidology, p11 

    The article examines the clinical utility of non-low-density lipoprotein cholesterol (HDL-C) in assessing coronary heart disease (CHD) risk by defining its calculation and reviewing studies of its superiority relative to serum triglycerides and LDL-C as a CHD risk predictor and goal for therapy.

  • Lipids as risk factors for stroke and CHD. DeFilippis, Andrew; Bhatia, Rinky; Jones, Steven // Cardiology Today;Jul2009, Vol. 12 Issue 7, p4 

    The article focuses on low density lipoprotein (LDL) as one of the risk factors for coronary heart disease (CHD).

  • The Medical Roundtable - CV Edition Spring 2011. Moser, Marvin // Medical Roundtable: Cardiovascular Edition;Spring2011, Vol. 2 Issue 2, p68 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the use of statins and other agents which lower low-density lipoproteins (LDL) choles­terol, the risk of residual coronary heart disease, and the use of spironolactone.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics